Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sedrakyan, A.
Right arrow Articles by Elefteriades, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sedrakyan, A.
Right arrow Articles by Elefteriades, J. A.
(Chest. 2003;123:1853-1857.)
© 2003 American College of Chest Physicians

Volume Expansion With Albumin Decreases Mortality After Coronary Artery Bypass Graft Surgery*

Artyom Sedrakyan, MD; Kathleen Gondek, PhD; David Paltiel, PhD and John A. Elefteriades, MD, FCCP

* From the School of Medicine (Drs. Sedrakyan, Paltiel, and Elefteriades), Yale University, New Haven; and Health Economics and Outcomes Research (Dr. Gondek), Bayer Corporation, West Haven, CT.

Correspondence to: John A. Elefteriades, MD, FCCP, Section of Cardiothoracic Surgery, Yale University School of Medicine, 121 FMB, 333 Cedar St, New Haven, CT; e-mail: john.elefteriades{at}yale.edu

Objectives: Albumin and nonprotein colloids (starches, dextran, and others) are used frequently as blood volume expanders in coronary artery bypass graft (CABG) surgery. The objective of this study was to determine differences between colloids with regard to patient characteristics and mortality rates.

Design and setting: Discharge data collected in the Solucient Clinical Pathways Database from 19,578 patients undergoing CABG surgery were analyzed.

Measurements: Patients receiving albumin and nonprotein colloids were compared with regard to baseline patient characteristics. A multiple regression model was developed to determine if albumin use was independently associated with mortality rates.

Results: Albumin was used in 8,084 cases (41.3%). The use of albumin and nonprotein colloids was not related to patient characteristics. Mortality was lower in the albumin group compared to the nonprotein colloid group (2.47% vs 3.03%, p = 0.02). In the multivariable logistic regression analysis, albumin use was associated with 25% lower odds of mortality compared to nonprotein colloid use (odds ratio, 0.80; 95% confidence interval, 0.67 to 0.96).

Conclusion: Colloid administration in CABG surgery was unrelated to patient characteristics. Albumin use appears to be associated with lower incidence of mortality after CABG surgery compared to nonprotein colloid use.

Key Words: albumin • coronary artery bypass grafting • mortality




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
Evidence-based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement
Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1247 - 1259.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.